Recently, six companies in the field of cell and gene therapy (CGT) in China have completed a new round of financing. Among them, the Series B financing of Anhui Eashare Biotech Co., Ltd. amounts to 235 million yuan, which is the highest. Next is the Series B+ financing of Rejuve Yilian Pharmaceutical Technology (Chengdu) Co., Ltd., which is nearly 100 million yuan.  

一 Metuk Biotechnology

On April 7th, Metuk (Shanghai) Biomedical Technology Co., Ltd. completed a Pre-A round of financing of approximately 10 million yuan. 

Metuk Biotechnology was established in February 2022. It is a developer of stem cell therapeutic drugs for senior pets, focusing on the research and development of drugs for treating geriatric diseases in pet cats and dogs. It mainly targets indications such as muscle atrophy, inflammatory enteritis, and osteoarthritis, and develops mesenchymal stem cell drugs (MSC) to improve the quality of life of senior pets. 

二 Eashare Biotech

On April 10th, Anhui Eashare Biotech Co., Ltd. completed a Series B financing of 235 million yuan. 

Eashare Biotech was established in January 2016. Centering around the core technology of iPSC, it has been continuously advancing the research and development of multiple types of cell drug pipelines in three major medical directions: anti-inflammatory repair, tumor immunity, and regenerative medicine. Among them, the therapeutic products of iPSC-derived mesenchymal-like cells (iMSC), iPSC-derived natural killer cells (iNK), and the therapeutic product NCR101 of genetically modified iPSC-derived mesenchymal-like cells (iMSC) have all obtained the clinical默示许可 (implied approval) from the Center for Drug Evaluation (CDE) of China. They are the first iMSC and iNK cell drugs approved for clinical trials in China, and NCR101 is the world's first genetically modified iMSC cell product approved for clinical trials.  

三 Rejuve Therapeutics

On April 11th, Rejuve Yilian Pharmaceutical Technology (Chengdu) Co., Ltd. completed a Series B+ financing of nearly 100 million yuan. 

Rejuve Therapeutics was established in August 2017, focusing on the field of induced pluripotent stem cell regeneration. Its core product, NouvNeu001, is the world's first chemically induced universal cell drug in the field of Parkinson's disease to enter the clinical stage. In November 2024, all subjects were enrolled in the Phase I clinical trial of NouvNeu001 for patients with moderate to advanced Parkinson's disease. The clinical results show that the subjects have good safety, and generally demonstrate significant improvements in motor function and quality of life. Especially in the low-dose group, the longest follow-up time of the subjects has exceeded 60 weeks, and the improvement effect on the patients' behavior is still steadily continuing. 

四 Eternal Life Tribe

On April 15th, Huangshan Eternal Life Tribe Stem Cell Technology Co., Ltd. completed an angel round of financing worth tens of millions of yuan. 

Eternal Life Tribe was established in September 2024, focusing on the research and development and industrialization of new drugs for immune cells and stem cells. It has successfully constructed a universal CAR-NK cell therapy technology system for solid tumors with independent intellectual property rights, and completed a number of in vitro and in vivo animal experiments. It plans to launch the IIT research and IND application work in 2025.  

五 Mebio Biotechnology

On April 17th, Beijing Mebio Pharmaceutical Biotechnology Development Co., Ltd. completed an A++ round of financing worth tens of millions of yuan. 

Mebio Biotechnology was established in July 2019. It is a manufacturer and seller of medical plastic surgery products, focusing on the field of cell medical treatment. It provides a series of comprehensive medical solutions including cells, biological materials, human-derived growth factors, human-derived collagen, etc. Its products include biological hydrogels such as Merite S +, Merite C +, and Merite A + for skin repair, as well as Class III medical devices such as collagen gels that can be used to treat mandibular retraction. 

六  Selenlily Biotechnology

On April 18th, Selenlily (Shanghai) Biotechnology Co., Ltd. completed its angel round of financing. 

Selenlily Biotechnology was established in April 2025. It focuses on personalized cell therapy and anti-aging. Based on the new generation of induced pluripotent stem cell (iPSC) technology, it develops innovative products and services for autologous cell therapy, regenerative medicine, and health management. 

Summary

With the continuous deepening of the understanding of cell characteristics and application mechanisms, the field of cell and gene therapy (CGT) is witnessing a continuous emergence of innovative achievements, attracting numerous enterprises to increase their investment and layout.

Recently, six highly promising enterprises in this field have successfully obtained a new round of financing, which provides strong financial support for them to accelerate the research and development of new cell drugs and their clinical transformation. In the current context of the rapid development of CGT technology, with the new round of financing, these enterprises are expected to overcome more traditional treatment challenges, develop more targeted and efficient personalized treatment plans, meet the urgent needs of patients for improving their quality of life and extending their survival period, further promote the widespread application of CGT treatment technology in the medical field, and inject new vitality into the development of the industry.